J&J's Tremfya Gets Its Blockbuster Wings
Executive Summary
The psoriasis drug was one of 10 J&J medicines that grew double digits in the third quarter, leading the company to raise guidance for the year.
You may also be interested in...
J&J’s Gorsky Hails Strong Performance By Immunology Therapies Tremfya, Stelara
A strong fourth quarter and full-year 2019 performance by J&J was driven by significant sales growth for Tremfya and Stelara. CFO Wolk said a $4bn opioids settlement remains on track.
J&J Settlement Leaves Teva As Sole Opioid Maker In Bellwether Trial
Four distributors and Walgreens also remain defendants; court to consider Teva's motion to dismiss if the trial results in a judgement against its subsidiaries. Seven-week trial could include 215 witnesses and 21,000 exhibits.
Keeping Track: A Duo Of RTOR Approvals, Thumbs Up For First Oral GLP-1 Treatment, And First Ebola Vaccine Nears US Market
The latest drug development news and highlights from our US FDA Performance Tracker.